Boehringer Ingelheim公司投资1.1亿美元加倍Respimat Soft吸入器的生产,增加雇员100名
- 互联网2012年11月8日 18:02 点击:1433
鉴于创新吸入系统不断增长的市场需求,以研究为导向的制药公司Boehringer Ingelheim投资约8500万欧元(1.1亿美元)到Dortmund 工厂以加倍他们的Respimat soft吸入器生产。
Boehringer Ingelheim Corporation to Double Respimat Soft Inhalers Production With $110 Million Investment, to Hire 100
10/30/2012 7:32:27 AM
Boehringer Ingelheim Pharmaceuticals | Jobs at Boehringer Ingelheim Pharmaceuticals
In view of increasing demand for innovative inhalation system, the research-driven pharma company - Boehringer Ingelheim Corporation is investing approximately Euro 85 million ($110 Million) in its Dortmund facility to double the Respimat soft inhalers production to 44 million annually by 2015. Will add 100 to Headacount, According to Sources.
A successful treatment of respiratory diseases depends on how much of the active substance enters into the patient's lung. Boehringer Ingelheim's Respimat soft inhaler and its long-lasting aerosol cloud effectively transport the active substance into the patient's lung.
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。